CIRM Funded Clinical Trials
Rebecsinib, an RNA Splicing and Base Editing Inhibitor to Target Cancer Stem Cells in Refractory Myeloid Malignancies
Disease Area:
Leukemia, Acute Myeloid (AML)
Trial Sponsor:
Aspera Biomedicines, Inc
Trial Stage:
Phase 1
Trial Status:
Launching
Targeted Enrollment:
N/A